Governor Phil Murphy signed legislation tightening New Jersey gun laws; the FDA temporarily suspended the ban on Juul sales; researchers found a cancer drug reduced risk of death among people hospitalized with COVID-19 by half.
New Jersey Governor Phil Murphy signed legislation Tuesday that would make it harder for individuals to obtain a handgun license and purchase high-capacity rifles in the state, The New York Times reported. The new legislation requires individuals to receive training to get a gun license and register firearms purchased out of state, and outlaws .50-caliber weapons. This news follows the Supreme Court’s decision to overturn a New York state gun law, and multiple shootings over Independence Day weekend.
The FDA temporarily suspended its ban on Juul sales, the agency announced Tuesday, clarifying this does not entirely rescind the ban. As reported by The Hill, the FDA found scientific issues unique to Juul’s application that require further review. During this time, Juul is also permitted to market its products in the United States. This announcement was made 2 weeks after the FDA ordered Juul to pull its e-cigarettes from the US market.
Experimental drug sabizabulin was initially developed for cancer treatment, but has been found to reduce the risk of death among people hospitalized with COVID-19 by half, The New York Times reported. According to a study published in The New England Journal of Medicine, the drug was more effective at reducing death compared with other drugs, and works by blocking cells from building microtubules. Because the study only included 134 patients, experts have expressed caution in interpreting the results, and encourage more, larger studies.
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More